KaydedilenlerDerginizi ekleyin

Dergiler / International Archives of Medical Research / 2019 / Cilt: 11 - Sayı: 2

Is there an association between immunohistochemical parameters of breast cancer and metabolic parameters obtained with 18F-fluorodeoxyglucose PET / CT?

Sadiye ALTUN TUZCU
Ayten GEZİCİ
Bekir TAŞDEMİR
İhsan KAPLAN
Hüseyin BÜYÜKBAYRAM
Feray ALTUN ÇETİN
Sayfa
51–61
Yayın Tarihi
2019-12-30
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusions: 1-SUV max, SUVmean and Ki-67 of Oestrogen receptor negative group were statistically higher than Oestrogen receptor positive group. 2-SUVmean and Ki-67 of progesterone receptor negative group were statistically higher than progesteron receptor positive group. 3- HER2 positive and/or triple negative breast cancers were not associated with 18F-FDG PET/CT metabolic parameters

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: The aim of our study to investigate relationship between 18F -fluorodeoxyglucose PET/CT (18F-FDG PET/CT) metabolic parameters and immunohistochemical factors in breast carcinomas.
📊
Temel Bulgular & Veri:Material and method: Patients with breast carcinomas who underwent 18F-FDG PET/CT imaging at our department between May 2018 and November 2019 were included in this study.
💡
Sonuç & Katkı:Conclusions: 1-SUV max, SUVmean and Ki-67 of Oestrogen receptor negative group were statistically higher than Oestrogen receptor positive group. 2-SUVmean and Ki-67 of progesterone receptor negative group were statistically higher than progesteron receptor positive group. 3- HER2 positive and/or triple negative breast cancers were not associated with 18F-FDG PET/CT metabolic parameters
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2018 Verileri
⚙️Değişkenler:breast cancer · Oestrogen receptor · 18F-FDG PET/CT

Abstract

Introduction: The aim of our study to investigate relationship between 18F -fluorodeoxyglucose PET/CT (18F-FDG PET/CT) metabolic parameters and immunohistochemical factors in breast carcinomas. Material and method: Patients with breast carcinomas who underwent 18F-FDG PET/CT imaging at our department between May 2018 and November 2019 were included in this study. A total of 146 female patients were included (aged 49.1 ± 13.4years; range, 26-87 years). PET scanning was performed in 3D mode from the skull ceiling to the middle of the thigh. Metabolic parameters such as TLG (Total lesion glycolysis), MTV (Metabolic tumor volume) , SUVmean and SUVmax values were calculated. We obtained the histopathological findings, including the size of invasive cancer, histological type, histological grade, ER and PR status, epidermal growth factor receptor (HER2) and Ki-67 of the primary tumor by reviewing the pathology reports. Result: SUV max and SUVmean of Oestrogen receptor negative group were statistically higher than Oestrogen receptor positive group (p=0.009). SUVmean of progesterone receptor negative group were statistically higher than progesterone receptor positive group (p=0.05). Ki-67 of the Oestrogen receptor negative group and progesterone receptor negative group were statistically higher than Oestrogen receptor and progesterone receptor positive group (p=0.001, 0,001 respectively). Both SUVmax and SUVmean of Ki-67 positive group were statistically higher than Ki-67negative group (p=0.0001). Conclusions: 1-SUV max, SUVmean and Ki-67 of Oestrogen receptor negative group were statistically higher than Oestrogen receptor positive group. 2-SUVmean and Ki-67 of progesterone receptor negative group were statistically higher than progesteron receptor positive group. 3- HER2 positive and/or triple negative breast cancers were not associated with 18F-FDG PET/CT metabolic parameters

🔖

Bu Makaleye Atıf Yap

TUZCU, S. A., GEZİCİ, A., TAŞDEMİR, B., KAPLAN, İ., BÜYÜKBAYRAM, H., ÇETİN, F. A. (2019). Is there an association between immunohistochemical parameters of breast cancer and metabolic parameters obtained with 18F-fluorodeoxyglucose PET / CT?. International Archives of Medical Research, Cilt: 11 - Sayı: 2, 51–61. https://ajindex.com/articles/764779

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Singletary, S. E. Rating the risk factors for breast cancer. Annals of Surgery, 2003;237(4), 474–482
  2. Barber, M. D., Jack, W., & Dixon, J. M. Diagnostic delay in breast cancer. British Journal of Surgery, 2004; 91(1), 49–53
  3. Osborne C.K., Yochmowitz M.G., Knight W.A., and McGuire W.L.: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: pp. 2884- 2888 4-Iqbal, N. Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Molecular Biology International, 2014; 852748(10), 7
  4. Koolen BB, Vrancken Peeters MJ, Wesseling J, et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2012;39:1830–8
  5. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med. 1998;28:290–302. 7-Choi BB, KimSH, Kang BJ, et al. Diffusion-weighted imaging and FDG PET/CT: predicting the prognoses with apparent diffusion coefficient values and maximum standardized uptake values in patients with invasive ductal carcinoma. World J Surg Oncol. 2012;10:126
  6. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87
  7. Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P. Correlation of 18F fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun. 2013;34:1055–67
  8. Gil-Rendo A, Martinez-Regueira F, Zornoza G, et al. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166–70
  9. Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35
  10. Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15:588–93
  11. Sanli Y, Kuyumcu S, Ozkan ZG, Isik G, Karanlik H, Guzelbey B. Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med. 2012;26:345–50
  12. Daisne J.-F., Sibomana M., Bol A., et al: Tri-dimensional automatic segmentati